Schreiner MediPharm develops film for blister pack blinding

Schreiner MediPharm, a Germany-based global provider of specialty pharmaceutical labels, has developed a film that shields participants in clinical trials from seeing any trial-threatening labeling information on the blister packs of placebos and active drugs.  

Efficient blinding of blister packs poses a challenge: the label must opaquely cover the pack but the film must be thin enough to allow the user to extract the pills easily. The new Schreiner MediPharm blinding film – simply placed on blister packs – utilizes a special ink that makes the thin label impervious to light while allowing users to extract pills from the blister without applying additional force. 

An important factor that makes the new film so efficient and reliable is its flexibility. Since the material consistently exhibits the same properties, it can be used on blister packs of various sizes and regardless of any individual cavity configurations. The film is also difficult to effectively detach; due to the specific properties of the material itis destroyed upon attempts to peel it off. 

‘Our new labeling solution helps avoid that users are influenced by the external appearance of a drug’s packaging,’ said Gene Dul, president of Schreiner MediPharm. ‘By neutralizing the blister packs of active drugs and placebos, investigators and subjects alike are shielded from discerning any information that may add unnecessary bias to clinical trials.’ 

Schreiner MediPharm’s US facility, a business unit of Schreiner Group LP, is located in Blauvelt, New York. 

Click here for more stories about Schreiner MediPharm on L&L.com.